Tivic Health Systems, Inc. (TIVC) Q2 2024 Earnings Call Transcript Summary
Tivic Health Systems, Inc. (TIVC) Q2 2024 Earnings Call Transcript Summary
Net loss for Q2 2024 was $1.3 million, improving from a $2.1 million loss in 2023.The following is a summary of the Tivic Health Systems, Inc. (TIVC) Q2 2024 Earnings Call Transcript:
以下是Tivic Health Systems, Inc.（TIVC）2024年第二季度业绩会交流摘要：
Financial Performance:
金融业绩：
Tivic Health reported lower ClearUP revenues for Q2 2024, totaling $140,000, a 12% decrease year-over-year, primarily due to a 27% decrease in unit sales offset by a 20% increase in the per-unit average sale price.
Gross profits for the three and six months ended June 30 were $30,000 and $197,000 respectively, showing an improvement in gross margin from 32% to 42%.
Net loss for Q2 2024 was $1.3 million, improving from a $2.1 million loss in 2023.
The company achieved a cash position of $3.7 million as of June 30, 2024, compared to $3.4 million at the end of 2023.
Tivic Health报告了2024年第二季度ClearUP收入下降的情况，总额为140,000美元，同比下降12％，主要是因为销售数量下降27％，而每单位平均销售价格上涨20％。
截至6月30日的三个月和六个月的毛利润分别为30,000和197,000美元，毛利率从32％提高到了42％。
2024年第二季度净亏损为130万美元，较2023年亏损210万美元有所改善。
截至2024年6月30日，该公司的现金余额为370万美元，而2023年底为340万美元。
Business Progress:
业务进展：
Tivic Health has made significant progress in the development of a noninvasive vagus nerve stimulation (VNS) system, in collaboration with the Feinstein Institutes for Bioelectronic Medicine.
The company completed Phase 1 trials showing profound biological effects, promising for the treatment of neurological, cardiovascular, and autonomic system diseases.
Tivic Health在与Feinstein Institutes for Bioelectronic Medicine合作的非侵入性迷走神经刺激（VNS）系统的开发方面取得了重大进展。
该公司完成了第一阶段试验，表现出深刻的生物效应，有望治疗神经系统、心血管系统和自主神经系统疾病。
Opportunities:
机会：
The new noninvasive VNS system represents a high-value medical target with potential to generate stronger shareholder returns.
Tivic's noninvasive bioelectronic platforms offer significant market differentiation and potential premium pricing, responding to unmet needs in medical-grade noninvasive VNS devices.
The company is exploring alternative monetization strategies for the ClearUP product.
新的非侵入性VNS系统代表着一个高价值的医疗目标，有可能带来更强的股东回报。
Tivic的非侵入式生物电平台为医用非侵入式VNS设备的未满足需求提供了明显的市场差异化和潜在溢价定价。
该公司正在探索ClearUP产品的替代变现策略。
Risks:
风险：
Tivic faces risks from operational cutbacks possibly impacting their ability to support new scientific advancements.
Threat of non-compliance with NASDAQ's $1.00 per share minimum bid price requirement, though they have until December 26 to regain compliance.
Tivic面临着运营裁员可能影响其支持新科学进展能力的风险。
尽管该公司有时间到12月26日恢复遵守纳斯达克的每股最低买入价格要求，但面临不遵守的威胁。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息，请参阅IR网站。本文只是为投资者提供参考，没有任何指导或推荐建议。